Global Autoimmune Polyglandular Syndrome Type 1 Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2022 –2029 |
 Market Size (Base Year) |
USD 228.00 Million |
 Market Size (Forecast Year) |
USD 347.26 Million |
 CAGR |
% |
| Major Markets Players |
全球自身免疫性多腺体综合征 1 型市场，按诊断（血清自身免疫筛查、终末器官功能测试、血液测试等）、治疗（药物、激素替代疗法等）、剂型（片剂、胶囊等）、给药途径（口服等）、发病年龄（儿童、成人、青少年）、最终用户（医院、专科诊所、家庭护理等）、分销渠道（医院药房、零售药房、网上药房等）划分 – 行业趋势和预测（至 2029 年）
市场分析和规模
自身免疫性多腺体综合征 (APS) 是一组内分泌异常，在免疫失调的人群中以不同的模式出现，可用于治疗和预测全身性或其他激素缺陷。APS1、APS2 和 APS3 是已确定的三个主要实体；由 FOXP3 基因突变引起的多内分泌病、免疫失调和肠病的罕见 X 连锁综合征也属于 APS。APS-1 治疗目前侧重于每个患者表现出的个体症状。任何内分泌激素缺乏的替代药物和关于这些缺陷的体征和症状的患者教育对于治疗效果至关重要。
Data Bridge Market Research 分析，2021 年自身免疫性多腺体综合征 1 型市场价值为 2.28 亿美元，预计到 2029 年将达到 3.4726 亿美元，在 2022 年至 2029 年的预测期内复合年增长率为 5.40%。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。
报告范围和市场细分
|
报告指标 |
细节 |
|
预测期 |
2022 至 2029 年 |
|
基准年 |
2021 |
|
历史岁月 |
2020（可定制为 2014 - 2019） |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
诊断（血清自身免疫筛查、终末器官功能测试、血液测试等）、治疗（药物、激素替代疗法等）、剂型（药片、胶囊等）、给药途径（口服等）、发病年龄（儿童、成人、青少年）、最终用户（医院、专科诊所、家庭护理等）、分销渠道（医院药房、零售药房、网上药房等） |
|
覆盖国家 |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Zydus Cadila (India), Lupin (India), Amneal Pharmaceuticals LLC. (U.S.), Cipla Inc. (U.S.), Aurobindo Pharma (India), Glenmark Pharmaceuticals Limited (India), Eli Lilly and Company (U.S.), Sun Pharmaceutical Industries Ltd. (India), Allergan (Ireland), Bristol-Myers Squibb Company (U.S.), Takeda Pharmaceutical Company Limited (Japan), Abbott (U.S.). LEO Pharma A/S (Denmark) |
|
Market Opportunities |
|
Market Definition
Autoimmune polyglandular syndrome type 1 (APS-1) is a rare and complex recessively inherited immune-cell malfunction illness characterized by several autoimmunities. It manifests as a set of symptoms that include potentially fatal endocrine and gastrointestinal dysfunctions. Autoimmune polyglandular syndrome type 1 (APS1) is a life-threatening disease for which there is no cure. Replacement of hormone deficits caused by autoimmune destruction of several endocrine organs is now the only therapy option.
Autoimmune Polyglandular Syndrome Type 1 Market Dynamics
Drivers
- Rise in the number of cases of autoimmune polyglandular syndrome type 1
The surging number of cases of autoimmune polyglandular syndrome type 1 is a major factor driving the market's growth rate during the forecast period of 2022-2029. Type 1 Autoimmune Polyglandular Syndrome (APS) is a rare inherited condition that affects the body's organs. AIRE gene mutation causes this disease entity. Hypoparathyroidism, Addison's disease, and chronic mucocutaneous candidiasis are the three characteristic clinical symptoms.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of autoimmune polyglandular syndrome type 1 market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, rising government initiatives to spread awareness about rare diseases and growing level of disposable income will result in the expansion of autoimmune polyglandular syndrome type 1 market. Along with this, favourable reimbursement policies and rising demand for disease-specific treatment will enhance the market's growth rate.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the autoimmune polyglandular syndrome type 1 market growth.
Moreover, the market's growth is fueled by rising technological advancement in diagnostic methods and emerging new markets. These factors will provide beneficial opportunities for the autoimmune polyglandular syndrome type 1 market growth.
Restraints/Challenges
On the other hand, the high cost associated with the treatment and diagnosis will obstruct the growth rate of the market. Developing economies' lack of healthcare infrastructure and dearth of skilled professionals will challenge the autoimmune polyglandular syndrome type 1 market. Additionally, lack of awareness among people and unfavourable healthcare policies will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This autoimmune polyglandular syndrome type 1 market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the autoimmune polyglandular syndrome type 1 market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
An uncommon disease, autoimmune polyglandular syndrome type 1, affects 1 in every 2 to 3 million babies. The prevalence is 1 in 90000 in Norway and 1 in 130000 in Ireland, however, it is more frequent in Sardinians and Iranian Jews, with prevalence rates of 1 in 14000 and 1 in 9000, respectively. There is no discernible gender disparity. The age at which the first manifestation occurs varies from 0.2 to 18 years.
自身免疫性多腺体综合征 1 型市场还为您提供详细的市场分析，以进行患者分析、预后和治疗。患病率、发病率、死亡率、依从率是报告中提供的一些数据变量。分析流行病学对市场增长的直接或间接影响，以创建更稳健、更队列的多变量统计模型，用于预测增长期的市场。
全球自身免疫性多腺体综合征 1 型市场范围
自身免疫性多腺体综合征 1 型市场根据诊断、治疗、剂型、给药途径、发病年龄、最终用户和分销渠道进行细分。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。
诊断
- 血清自身免疫筛查
- 终末器官功能测试
- 血液检查
- 其他的
治疗
- 药物
- 抗真菌剂
- 氟康唑
- 伊曲康唑
- 骨化三醇
- 皮质类固醇
- 激素替代疗法
- 其他的
剂型
- 药片
- 胶囊
- 其他的
给药途径
- 口服
- 其他的
发病年龄
- 童年
- 成人
- 青少年
最终用户
- 医院
- 专科诊所
- 家庭护理
- 其他的
分销渠道
- 医院药房
- 零售药店
- 网上药店
- 其他的
自身免疫性多腺体综合征 1 型市场区域分析/见解
对 1 型自身免疫性多腺体综合征市场进行了分析，并按上述国家、诊断、治疗、剂型、给药途径、发病年龄、最终用户和分销渠道提供了市场规模洞察和趋势。
自身免疫性多腺体综合征 1 型市场报告涵盖的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲的其他地区
北美在市场份额和市场收入方面占据 1 型自身免疫性多腺体综合征市场的主导地位，并将在预测期内继续保持主导地位。这是由于 1 型自身免疫性多腺体综合征的患病率不断上升，医疗保健支出不断增加，将进一步推动该地区市场的增长率。此外，主要关键参与者的不断增加也将进一步推动该地区市场的增长率。
由于该地区医疗保健基础设施的发展，预计亚太地区将在 2022-2029 年预测期内实现增长。此外，政府举措的不断增加将进一步推动该地区市场的增长率。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
竞争格局和自身免疫性多腺体综合征 1 型市场份额分析
自身免疫性多腺体综合征 1 型市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对自身免疫性多腺体综合征 1 型市场的关注有关。
自身免疫性多腺体综合征 1 型市场的一些主要参与者包括：
- 辉瑞公司（美国）
- 葛兰素史克公司 (英国)
- 诺华公司（瑞士）
- Mylan NV（美国）
- Teva Pharmaceutical Industries Ltd.（以色列）
- 赛诺菲（法国）
- F. Hoffmann-La Roche Ltd.（瑞士）
- Zydus Cadila（印度）
- 鲁冰花（印度）
- Amneal Pharmaceuticals LLC.（美国）
- Cipla Inc.（美国）
- Aurobindo Pharma（印度）
- Glenmark 制药有限公司（印度）
- 礼来公司 (美国)
- 太阳制药工业有限公司 (印度)
- 艾尔建（爱尔兰）
- 百时美施贵宝公司 (美国)
- 武田药品工业株式会社 (日本)
- 雅培（美国）
- LEO Pharma A/S（丹麦）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
